CTLA-4 inhibitors have shown efficacy in treating various types of cancer, most notably melanoma. Ipilimumab has been approved by the FDA for the treatment of advanced melanoma. Additionally, CTLA-4 inhibitors are being investigated in clinical trials for their potential to treat other cancers, including renal cell carcinoma, non-small cell lung cancer, and prostate cancer.
